Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Protalix Biotherapeutics (PLX)

Protalix Biotherapeutics (PLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 95,203
  • Shares Outstanding, K 71,581
  • Annual Sales, $ 47,640 K
  • Annual Income, $ -14,930 K
  • 60-Month Beta 0.91
  • Price/Sales 1.50
  • Price/Cash Flow N/A
  • Price/Book 2.56
Trade PLX with:

Options Overview Details

View History
  • Implied Volatility 370.49% ( +148.17%)
  • Historical Volatility 58.01%
  • IV Percentile 98%
  • IV Rank 69.64%
  • IV High 526.36% on 10/26/23
  • IV Low 13.02% on 10/02/23
  • Put/Call Vol Ratio 0.02
  • Today's Volume 65
  • Volume Avg (30-Day) 128
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 2,641
  • Open Int (30-Day) 2,757

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.05
  • Growth Rate Est. (year over year) +1,998,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2693 +0.06%
on 03/18/24
1.6800 -24.40%
on 03/01/24
-0.2000 (-13.61%)
since 02/16/24
3-Month
1.2693 +0.06%
on 03/18/24
1.9000 -33.16%
on 12/26/23
-0.5000 (-28.25%)
since 12/18/23
52-Week
1.2100 +4.96%
on 11/08/23
3.5500 -64.23%
on 05/05/23
-0.7600 (-37.44%)
since 03/17/23

Most Recent Stories

More News
Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors

/PRNewswire / Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of...

IMTX : 11.83 (-1.50%)
PLX : 1.2700 (-4.51%)
Protalix BioTherapeutics to Host In-Person KOL Breakfast following the Approval of Elfabrio® in both the United States and the European Union for Adults with Fabry Disease

/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization...

PLX : 1.2700 (-4.51%)
Protalix BioTherapeutics Issues Letter to Stockholders

/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization...

PLX : 1.2700 (-4.51%)
Protalix BioTherapeutics set to join Russell 3000® Index

/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization...

PLX : 1.2700 (-4.51%)
Protalix BioTherapeutics Announces $20 Million Milestone Payment from Chiesi Global Rare Diseases

/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization...

PLX : 1.2700 (-4.51%)
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease

/PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected...

PLX : 1.2700 (-4.51%)
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease

/PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected...

PLX : 1.2700 (-4.51%)
Protalix BioTherapeutics Announces First Patient Dosed in First in Human Phase I Clinical Trial of PRX-115 for the Treatment of Severe Gout

/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and...

PLX : 1.2700 (-4.51%)
Protalix BioTherapeutics Issues Statement Related to Silicon Valley Bank and Signature Bank

/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and...

PLX : 1.2700 (-4.51%)
Protalix BioTherapeutics Reports Fiscal Year 2022 Financial and Business Results

/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and...

PLX : 1.2700 (-4.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Protalix BioTherapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of recombinant therapeutic proteins. The company's product pipeline includes ProCellEx(R). Protalix BioTherapeutics Inc. is based in CARMIEL, Israel.

See More

Key Turning Points

3rd Resistance Point 1.3709
2nd Resistance Point 1.3505
1st Resistance Point 1.3102
Last Price 1.2700
1st Support Level 1.2495
2nd Support Level 1.2291
3rd Support Level 1.1888

See More

52-Week High 3.5500
Fibonacci 61.8% 2.6561
Fibonacci 50% 2.3800
Fibonacci 38.2% 2.1039
Last Price 1.2700
52-Week Low 1.2100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar